NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

For full-year 2013, revenues rose to $134,245 from $109,289 in 2012, the San Diego-based firm said in its Form 10-K filed with the US Securities and Exchange Commission. Its net loss in 2013 was $9.2 million, or $50.80 per share, compared to a net loss of $12.3 million, or $76.43 per share, in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.